{"tid":1875666,"cid":5,"subCid":10,"title":"中国博瑞醫藥稱成功仿製瑞德西韋原料藥  已批量生產","createTime":"2020-02-12T02:26:48.000Z","updateTime":"2020-02-12T03:05:43.000Z","uid":184679,"like":0,"dislike":2,"uniUserReply":5,"replies":[{"pid":"50993d3555652aa8ed254889e5f325645e2a3262","tid":1875666,"uid":184679,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2020-02-12T02:26:48.000Z","msg":"美國實驗性抗病毒藥物「瑞德西韋」被認為可能是治療新型冠狀病毒的藥物。大陸科創板上市公司博瑞醫藥昨晚公告，公司成功開發瑞德西韋原料藥合成工藝技術和製劑技術，並已經批量生產出瑞德西韋原料藥。<br />\n<br />\n證券時報報導，博瑞醫藥今（12）日開盤漲停。公司11日晚間公告，近日成功仿製開發瑞德西韋原料藥合成工藝技術和制劑技術，瑞德西韋製劑批量化生產正在進行中。<br />\n<br />\n博瑞醫藥表示，公司完成瑞德西韋原料藥的仿製和製劑生產後，需經過藥物臨床試驗、藥品審批等多個環節。若瑞德西韋最終轉化為產品投入市場，需要獲得Gilead公司作為專利權人的授權；這一過程將存在重大不確定性。<br />\n<br />\n截至目前，公司在瑞德西韋的原料藥和制劑開發和生產中已發生的成本預計約為人民幣500萬元，後續進一步放大生產，預計還需要投入約人民幣1,000萬元。<br />\n<br />\n博瑞醫藥強調，該項研發與現有其他業務相互獨立，公司其他業務運營正常。公司開發瑞德西韋是為了響應大陸國家號召，儘早獲得抗擊新型冠狀病毒（2019-nCoV）疫情治療藥物。若該產品能夠獲批上市，疫情期間主要通過捐贈等方式供應給相關病人，預計不會對公司2020年度經營業績產生重大影響。<br />\n<br />\n<a href=\"https://money.udn.com/money/story/5603/4338380\" data-sr-url=\"https://r.lihkg.com/link?u=https%3A%2F%2Fmoney.udn.com%2Fmoney%2Fstory%2F5603%2F4338380&d=k4A9UPuxEtmwSexvyTVA%2Bb9EqtgOipuK5hw8%2B6jdv%2Bo%3D&h=e5350d02\" data-auto-link target=\"_blank\">https://money.udn.com/money/story/5603/4338380</a>"},{"pid":"78b681b17e0b3c6a0512ec47b6282acc2b658bcc","tid":1875666,"uid":88939,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2020-02-12T02:42:36.000Z","msg":"厲害了<img src=\"/assets/faces/normal/dead.gif\" class=\"hkgmoji\" />"},{"pid":"e56492347677750871b7a1ff8fc089a557f3ac30","tid":1875666,"uid":155095,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2020-02-12T02:45:31.000Z","msg":"<img src=\"https://i.ytimg.com/vi/wjFRYAZpe7s/maxresdefault.jpg\" data-thumbnail-src=\"https://i.lih.kg/thumbnail?u=https%3A%2F%2Fi.ytimg.com%2Fvi%2FwjFRYAZpe7s%2Fmaxresdefault.jpg&h=c1bd0a6b&s={SIZE}\" /><br />\n<br />\n<img src=\"https://cdn.hk01.com/di/media/images/3691153/org/613da8871b02006585c467d3591052b0.jpg/RDOiy2MTILb64W7dVnyFTnZ1rN2oWyCwuco0pbnKNKU?v=w1920r16_9\" data-thumbnail-src=\"https://i.lih.kg/thumbnail?u=https%3A%2F%2Fcdn.hk01.com%2Fdi%2Fmedia%2Fimages%2F3691153%2Forg%2F613da8871b02006585c467d3591052b0.jpg%2FRDOiy2MTILb64W7dVnyFTnZ1rN2oWyCwuco0pbnKNKU%3Fv%3Dw1920r16_9&h=c9432b61&s={SIZE}\" />"},{"pid":"410d480de8f09f65a1ed7a642c704ce73afabbef","tid":1875666,"uid":66994,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2020-02-12T02:54:56.000Z","msg":"A貨就A貨啦"},{"pid":"30b4bceabe32a0bd88570d3c8d62c07ba80f6898","tid":1875666,"uid":52577,"like":0,"dislike":0,"score":0,"citedBy":0,"replyTime":"2020-02-12T03:05:43.000Z","msg":"唔係話自己研發申請專利咩？<br />\n咁做咩要仿製？<img src=\"/assets/faces/dog/haha.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/dog/haha.gif\" class=\"hkgmoji\" /><img src=\"/assets/faces/dog/haha.gif\" class=\"hkgmoji\" />"}]}